Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 20 September

Bell Direct
September 20, 2024

Morning Bell 19 September

Bell Direct
September 19, 2024

Morning Bell 18 September

Bell Direct
September 18, 2024

Morning Bell 17 September

Bell Direct
September 17, 2024

Morning Bell 16 September

Bell Direct
September 16, 2024

Weekly Wrap 13 September

Bell Direct
September 13, 2024

Morning Bell 13 September

Bell Direct
September 13, 2024

Morning Bell 12 September

Bell Direct
September 12, 2024

8 minutes with 8 executives

Bell Direct
September 11, 2024

Morning Bell 11 September

Bell Direct
September 11, 2024

Morning Bell 10 September

Bell Direct
September 10, 2024

Morning Bell 9 September

Bell Direct
September 9, 2024